Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a heart drug combo help COPD lungs?

NCT ID NCT05567562

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether taking two common blood thinners (aspirin and clopidogrel) for two weeks can improve blood flow in the lungs of smokers with COPD. Fifteen current or former smokers with and without COPD participated. The goal was to see changes on a special CT scan, not to treat symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
aspirin and clopidogrel (dual anti-platelet therapy)
What this could lead to
If it works, this could point toward a new way to improve blood flow in the lungs for people with COPD.
What could go wrong
This is a very small, early-phase study with only 15 participants. It is designed to measure changes in blood flow, not to prove any treatment benefit. Results may not apply to all COPD patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

15 people

The number who actually took part.

Started

Mar 2024

Finished

Feb 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria - COPD Cases: * COPD (FEV1/FVC \< 0.7, FVC \>= LLN), GOLD Stage I/II/III (FEV1 \>= 40%) * Current or former smoker of at least 10 pack years Inclusion Criteria - Controls: * Normal lung function (FEV1/FVC \>= 0.7, FEV1 and FVC \>= LLN) * Current or former smoker of at least 10 pack years Exclusion Criteria: * Platelet count \< 150,000/dL or self-report of a bleeding disorder; * Regular use of aspirin, clopidogrel or another antiplatelet medication; * Allergy to aspirin, clopidogrel, albuterol or iodine/IV contrast; * BMI \> 35; * History of intracranial hemorrhage, severe GI bleed or other life-threatening bleed; * Use of blood thinner (e.g. warfarin, lovenox or novel oral anti-coagulants); * Continuous use of supplemental oxygen at home; * Regular use of an NSAID; * Daily use of oral steroids, theophylline, roflumilast, or loop diuretics; * History of organ transplant or autoimmune disease on systemic therapy (rheumatoid arthritis, lupus); * Use of a biologic medication with regular injections; * Other current lung disease (interstitial lung disease, idiopathic pulmonary fibrosis, asthma); * IV drug use within the last year; * History of lung surgery to remove part of the lung; * Known bullae or advanced destructive emphysema in more than 1/3 of the lungs; * Treatment for cancer (systemic therapy or surgical/radiation within the thorax) in the last 12 months; * Known diagnosis of pulmonary hypertension; * Known systolic heart failure (RV or LV EF \< 40%); * Acute or chronic renal insufficiency (estimated glomerular filtration rate \[GFR\] \<60 mL/min/1.73 m2 or self-report). GFR will be calculated using the CKD-EPI equation; * Current or planned pregnancy in the next year; * Regular marijuana smoking; * Exacerbation of respiratory symptoms within the previous 6 weeks, such as that requiring hospitalization, oral prednisone or antibiotics to control symptoms, or longer and not yet returned to baseline; and * Chest, abdominal or eye surgery, or a heart attack or stroke, within the last 3 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.